Dear Editor,

In a recent issue of the JCMM, Sfrent-Cornateanu *et al.*\[[@b1]\] described an association between the G/A single nucleotide polymorphism (SNP) in the position -597 of the IL-6 gene, with disease activity and disability, but not with the disease per se, in 20 systemic sclerosis (SSc) patients.The idea of a disease-modifying, -rather than a disease-susceptibility, point mutation is intriguing and in line with others findings in the context of SSc \[[@b2]\]. Nonetheless, the inability to depict such an association could be attributable to the low number of subjects and indeed the possibility of a type II error in such a small group of patients is more than remote. Based on previous findings that indicate that the G/C substitution at position -174 -in complete linkage disequilibrium with the G/A-597 SNP-, is associated with an increased IL-6 production *in vitro* and *in vivo*\[[@b6]\], the authors anticipated a decreased risk for SSc in CC -174 (AA -597) individuals compared to GG -174 (GG -597) subjects and claimed further studies in larger patient groups to verify this hypothesis and their findings as well.

The present retrospective case-control study was conducted on 196 consecutive patients with a diagnosis of SSc (ACR criteria \[[@b7]\]), referring to our outpatient clinic. One-hundred-ninety-six healthy sex-, ageand ethnically-matched subjects were included as controls. The number of patients and the case-to control ratio were chosen so as to obtain a power of 0.75 with an alpha level equal to 0.05 with a putative difference of 9% in the prevalence of the G allele at position -174; power calculation was carried out with the PS Program \[[@b8]\] and by using the frequencies of the G/C -174 SNP previously published in the Italian population as reference \[[@b9]\]. Clinical procedures for the study were those described by Sfrent-Cornateanu \[[@b1]\]: patients were categorized as having the limited cutaneous (lcSSc) or the diffuse cutaneous (dcSSc) subset of the disease according to LeRoy *et al.*\[[@b10]\] and were asked to complete the Disability Index of the Health Assessment Questionnaire (HAQ-DI) \[[@b11]\]; disease activity was assessed according to the European Scleroderma Study Group (ESsSG) \[[@b12]\] and by an experienced physician (AS) on a 100 mm visual analogue scale (VAS). The G/C -174 SNP was determined with sequence-specific primers by a commercial kit (CTS PCR-SSP TRAY, from the Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany) as previously described \[[@b4]\]. All the participating subjects gave written consent for the research. Statistics were carried out with the SPSS package, ver 15.0 (SPSS Chicago, IL).

The majority of patients were females (n = 178, 90.8%), with the lcSSc subset of the disease (n = 142, 72.4%), with a mean age and disease duration of 59.6 ± 12.4 and 11.2 ± 6.8 years, respectively. The distribution of the G/C-174 genotypes in patients and controls was consistent with Hardy-Weinberg\'s equilibrium; the genotypes or the alleles of the G/C -174 SNP were equally distributed between cases and controls ([Table](#tbl1){ref-type="table"}). HAQDI, VAS or ESsSG activity scores, as well as the most recent forced vital capacity% of predicted values, diffusing capacity for carbon monoxide% of predicted values, pulmonary systolic pressure on echocardiogram and total skin scores \[[@b13]\] were equally distributed among the G/C 174 genotypes or alleles ([Table](#tbl1){ref-type="table"}).

###### 

Interleukin-6 G/C -174 single nucleotide polymorphism in 196 Italian systemic sclerosis patients and 196 healthy ethnically-matched controls

  **Variable**          **Genotype**   **Allele**                                
  --------------------- -------------- ------------- ------------- ------------- -------------
  **Controls, n (%)**   89 (45.4%)     87 (44.4%)    20 (10.2%)    265 (67.6%)   127 (32.4%)
  **SSc, n (%)**        84 (42.9%)     94 (48%)      18 (9.2%)     262 (66.8%)   130 (33.2%)
  **lcSSc**             63 (44.4%)     68 (47.9%)    11 (7.7%)     194 (68.3%)   90 (31.7%)
  **dcSSc**             21 (38.9%)     26 (48.1%)    7 (13%)       68 (63%)      40 (37%)
  **HAQ-DI, score**     0.86 ± 0.77    0.67 ± 0.6    1.2 ± 0.58    0.79 ± 0.71   0.8 ± 0.63
  **ESsSG, score**      1.52 ± 1.25    1.71 + 1.21   1.33 ± 1.7    1.58 ± 1.27   1.61 ± 1.18
  **VAS, mm**           38.3 ± 30.1    42.5 ± 28.7   42 ± 22.4     39.8 ± 29.3   42.4 ± 26.8
  **FVC,% pred**        82.7 ± 23.7    81.2 ± 20.8   77.8 ± 24.9   82.2 ± 22.5   80.2 ± 21.8
  **DLco,% pred**       56.2 ± 19.6    57.2 ± 19.6   57.2 ± 18.6   56.7 ± 19.5   57.4 ± 19.2
  **PAP, mmHg**         32.2 ± 18      29 ± 14.2     38.9 ± 17.7   30.1 ± 16.7   31.6 ± 15.6
  **mRSS**              5.3 ± 5        5.7 ± 5.6     6.7 ± 4.7     5.5 ± 5.2     6 ± 5.3

Variables expressed as mean ± standard deviation, except where otherwise indicated. Statistical analysis performed by the chi-square test, Student\'s t-test (between alleles) or ANOVA (among genotypes); *P*-value not significant for all the comparisons. SSc, systemic sclerosis, -lcSSc, limited- and -dcSSc, diffuse- \[[@b10]\]. HAQ-DI, Health Assessment Questionnaire Disability Index \[[@b11]\]; ESsSG, European Scleroderma Study Group activity score \[[@b12]\]; VAS, visual analog scale (1--100 mm); FVC, forced vital capacity; DLco, diffusing capacity for carbon monoxide; PAP, pulmonary systolic pressure; mRSS, modified Rodnan Skin Score \[[@b13]\].\]

The G/C -174 (G/A -597) SNP seems thus to play no role either in SSc-susceptibility or in SSc activity or disability, as suggested by Sfrent-Cornateanu *et al.*\[[@b1]\]. The latter results are not unexpected, as functional *e.g.* HAQ-DI) and activity scores (*e.g.* ESsSG and VAS) are "dynamic" measures that reflect the patient\'s short term condition (*e.g.* within 1--4 weeks) and may change over time and in response to therapy \[[@b14]\], being hence inadequate for comparison with a "static" genetic variable. Of course, at the moment we cannot definitively rule out the possibility that the G/C -174 (G/A -597) SNP might be associated with other aspects of the disease when a more thorough analysis is carried out in a prospective fashion on selected outcomes variables or in selected subgroup of patients, even if this possibility seems quite remote.

The present work was supported by a grant from the Fondazione CARIPLO (CAssa di RIsparmio delle Province LOmbarde) and by a grant from GILS (Gruppo Italiano per la Lotta alla Sclerodermia).

[^1]: Variables expressed as mean ± standard deviation, except where otherwise indicated. Statistical analysis performed by the chi-square test, Student\'s t-test (between alleles) or ANOVA (among genotypes); *P*-value not significant for all the comparisons. SSc, systemic sclerosis, -lcSSc, limited- and -dcSSc, diffuse- \[10\]. HAQ-DI, Health Assessment Questionnaire Disability Index \[11\]; ESsSG, European Scleroderma Study Group activity score \[12\]; VAS, visual analog scale (1--100 mm); FVC, forced vital capacity; DLco, diffusing capacity for carbon monoxide; PAP, pulmonary systolic pressure; mRSS, modified Rodnan Skin Score \[13\].\]
